艾昆纬-革新医疗事务-我们已准备好与您携手，重新定义医疗参与的未来（英）

Revolutionizing Medical AffairsWe are ready to redefine the future of medical engagement with you• Unified global data fabric• Forward-thinking innovation• Integrated technology2 | Revolutionizing Medical AffairsFPOUnlock the power of KOL collaboration: transforming expertise into impactPartnering with Key Opinion Leaders (KOLs), typically thought leaders in their respective fields, is crucial for driving innovation and enhancing credibility within the life sciences. In the pharmaceutical industry, thought leaders are referred to by various names depending on the company. Common terms include KOL (Key Opinion Leader), EE (External Expert), KEE (Key External Expert), TL (Thought Leader), and SE (Scientific Expert). Despite the different titles, they all represent the same concept of leveraging the expertise and influence of respected professionals. Effective Thought Leader Engagement (TLE) educates the medical community, fosters trust, and ultimately benefits patients, and is essential for successful product launches and swift commercial success. While many pharmaceutical companies want to invest in TLE, they struggle with where to start and how to demonstrate its impact. Challenges include identifying the right KOLs, maintaining authentic partnerships, ensuring regulatory compliance, and balancing short-term and long-term strategies.iqvia.com | 3The risks of ineffective TLEWithout robust TLE solutions, pharmaceutical companies encounter difficulties in effectively engaging KOLs due to unharmonized data, ineffective engagement methods, and lack of actionable insights. These issues result in suboptimal strategies and limited flexibility in managing growing needs and market shifts towards more scientifically driven conversations. Consequently, companies miss opportunities for innovation, minimizing the alignment between products and real-world needs and reducing their ability to shape industry conversations and stay competitive. Investing in effective TLE tools is essential to avoid these pitfalls and to ensure sustained growth and impact. Pharma companies that prioritize executing well with structured TLE strategies often report enhanced product adoption rates, more successful product launches, and stronger stakeholder trust.Lack of integration of HCP insights in planningLack of impact understandingDisconnected point solutionsLimited activity coordinationInability to seamlessly identify HCPs, search and filter based on comprehensive profile and engagement data, as well as apply AI/ML-driven insights.Few visualizations available for executive and strategic decisions while unclear impact metrics inhibit synthesis of multiple applicable TA dimensions.Use of disconnected point solutions to try to meet stakeholder engagement requirements with band-aided integration and future technological uncertainties.Non-integrated data and rigid tools fail to support global objectives and cross-functional teams to strategically plan and execute efficiently with